Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Accured Expenses (2016 - 2025)

Seres Therapeutics' Change in Accured Expenses history spans 11 years, with the latest figure at $633000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 106.96% year-over-year to $633000.0; the TTM value through Sep 2025 reached -$11.1 million, down 147.6%, while the annual FY2024 figure was -$10.2 million, 164.38% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $633000.0 at Seres Therapeutics, up from -$352000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $38.6 million in Q3 2021 and bottomed at -$19.0 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is $65000.0 (2021), against an average of $2.5 million.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 6495.04% in 2023 before it tumbled 756.87% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $65000.0 in 2021, then soared by 520.0% to $403000.0 in 2022, then surged by 6495.04% to $26.6 million in 2023, then plummeted by 126.12% to -$6.9 million in 2024, then surged by 109.12% to $633000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Change in Accured Expenses are $633000.0 (Q3 2025), -$352000.0 (Q2 2025), and -$4.4 million (Q1 2025).